These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35971794)

  • 1. Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections.
    Lahue BJ; Mallick R; Zhang X; Heidt J; Song Y; Koenig AS; Espinoza G
    Immunotherapy; 2022 Oct; 14(15):1245-1261. PubMed ID: 35971794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infections in secondary immunodeficiency patients treated with Privigen
    Mallick R; Divino V; Smith BD; Jolles S; DeKoven M; Vinh DC
    Leuk Lymphoma; 2021 Dec; 62(14):3463-3473. PubMed ID: 34569910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A summertime pause in immunoglobulin replacement therapy: a prospective real-world analysis.
    Hémar V; Rivière E; Greib C; Machelart I; Roucoules M; Prot C; Pellegrin JL; Viallard JF; Lazaro E
    Immunotherapy; 2021 Dec; 13(18):1491-1499. PubMed ID: 34743547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
    Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
    Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utilization of intravenous or subcutaneous immunoglobulins in secondary immune deficiency (ULTIMATE): A retrospective multicenter study.
    Legendre P; Chahwan D; Marjanovic Z; Vignon M; Hermine O; Lortholary O; Morelle G; Darrodes M; Kahn JE; Ouzegdouh M; Chaibi P; Montestruc F; Caumont-Prim A; Le Jouan M; Hassani Y; Godeau B; Durand-Zaleski I; Mouthon L
    Clin Immunol; 2020 Jun; 215():108419. PubMed ID: 32289463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
    Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
    Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of immunoglobulin replacement therapy in secondary immunodeficiency to hematological cancer: a single center observational study.
    Guerola LDC; Sacristán AAG; Portolés A; Jasso M; Guerra-Galán T; de la Fuente-Munoz E; Palacios-Ortega M; Fernández-Arquero M; Cuesta-Mínguez C; Rodríguez-Sanz A; Peña-Cortijo A; Polo M; Morales MM; Anguita-Mandly E; Benítez Jiménez T; Benavente Cuesta C; Sánchez-Ramón S
    Front Immunol; 2024; 15():1413231. PubMed ID: 38989286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
    Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
    Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).
    Syed MN; Kutac C; Miller JM; Marsh R; Sullivan KE; Cunningham-Rundles C; Fuleihan RL; Kheradmand F; Hajjar J
    J Clin Immunol; 2022 Oct; 42(7):1545-1552. PubMed ID: 35779201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
    Patel V; Cowan J
    Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adequate IVIG dosing is associated with an improved long-term outcome in secondary immunodeficiency: A prospective, non-interventional study.
    Bauhofer A; Balaban Ü; Schimo S; Mayer M; Schüttrumpf J; Borte S
    Int J Clin Pharmacol Ther; 2024 Oct; 62(10):448-459. PubMed ID: 39078054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.
    Shillitoe B; Hollingsworth R; Foster M; Garcez T; Guzman D; Edgar JD; Buckland M
    Clin Med (Lond); 2018 Oct; 18(5):364-370. PubMed ID: 30287427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule.
    Sim B; Ng JY; Teh BW; Talaulikar D
    Leuk Lymphoma; 2023 Jan; 64(1):18-29. PubMed ID: 36218218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and burden of infection in patients with chronic lymphocytic leukemia and secondary immunodeficiency: a retrospective database study.
    Siffel C; Richter J; Anderson-Smits C; Kamieniak M; Ren K; Shah D; Davids MS
    Ann Hematol; 2024 Nov; 103(11):4567-4580. PubMed ID: 39264434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of secondary immunodeficiency in hematological malignancies in the era of modern oncology.
    Shah N; Mustafa SS; Vinh DC
    Crit Rev Oncol Hematol; 2023 Jan; 181():103896. PubMed ID: 36528276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review.
    Cinetto F; Francisco IE; Fenchel K; Scarpa R; Montefusco V; Pluta A; Wolf HM
    Expert Rev Hematol; 2023 Apr; 16(4):237-243. PubMed ID: 37009667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence.
    Soumerai JD; Yousif Z; Gift T; Desai R; Huynh L; Ye M; Banatwala A; Clear L; Pinaire M; Belsky G; Hsieh YG; Herrick C; Darnell EP; Duh MS; Sanchirico M; Murphy SN
    Blood Adv; 2024 Aug; 8(16):4239-4249. PubMed ID: 38904477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments.
    Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
    Hematology; 2019 Dec; 24(1):173-182. PubMed ID: 30458690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
    Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
    Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.